Multidirectional inhalation therapy of acute rhinosinusitis
https://doi.org/10.21518/2079-701X-2019-8-28-32
Abstract
In the article is discussed the problem of antibiotic resistance, widespread and not always justified use of systemic antibiotics in the treatment of acute rhinosinusitis. The main spectrum of bacterial pathogens of acute rhinosinusitis, their sensitivity and resistance are showed, including in the Russian Federation. Presents topical inhalational drug Fluimucil IT contains mucolitic and antibiotic as a possible replacement of systemic antibiotics, in conjunction with its better tolerability, including in children, and less pronounced side effects.
About the Authors
S. V. Morozova
Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of
the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Dr. of Sci. (Med), Professor of the Department of Ear, Throat and Nose Diseases of the Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Dr. of Sci. (Med), Professor of the Department of Ear, Throat and Nose Diseases of the Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of the Ministry of Health of the Russian Federation (Sechenov University)
V. M. Svistushkin
Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of
the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Dr. of Sci. (Med), Professor, Head of the Department of Ear, Throat and Nose Diseases, Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov, Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Dr. of Sci. (Med), Professor, Head of the Department of Ear, Throat and Nose Diseases, Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov, Ministry of Health of the Russian Federation (Sechenov University)
L. S. Karapetyan
Federal State Autonomous Educational Institution of Higher Education First Moscow State Medical University named after I.M. Sechenov of
the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Assistant of the Department of Otorhinolaryngology of the Federal State Autonomous Educational Institution of Higher Education «First Moscow State Medical University named after I.M. Sechenov» of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Assistant of the Department of Otorhinolaryngology of the Federal State Autonomous Educational Institution of Higher Education «First Moscow State Medical University named after I.M. Sechenov» of the Ministry of Health of the Russian Federation (Sechenov University)
References
1. Minzdravsoczrazvitiya Rossii. Zabolevaemost` naseleniya Rossii v 2007 g. Statisticheskie danny`e. Chast` I. 2008.] (In Russ.)
2. Rational antimicrobial pharmacotherapy. Guidelines for practitioners. Under ed. Yakovleva V.P., Yakovleva S.V. M.: Litterra, 2003. 1008 s.] (In. Russ.)
3. Rachina S.A., Kozlov R.S., Tatochenko V.K. et al. Practice of treatment of acute respiratory infections in children in outpatient polyclinics of the Russian Federation: results of multicenter pharmacoepidemiological research. Clinical pharmacology and therapy [Klinicheskaya farmakologiya i terapiya] 2016;2:20–27.] (In Russ.)
4. Acute sinusitis. Clinical recommendations of the national medical association of otorhinolaryngologists. MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION 2016.] (In Russ.)
5. Svistushkin V.M., Savvateeva D.M. Current trends in the treatment of patients with acute rhinosinusitis. RMJ. Otorhinolaryngology. [RMZh. Otorinolaringologiya]. 2016, 2016;4:251-254.]. (In Russ.)
6. Fokkens W.J., Lund V.J., Mullol J., Bachert C., Alobid I., Baroody F. et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50(1):1-12. https://doi.org/10.4193/ Rhino50E2/.
7. Anon J.B., Jacobs M.R., Poole M.D., Ambrose P.G., Benninger M.S., Hadley J.A., Craig W.A. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg. 2004 Jun;130(6):794-6. https://doi.org/10.1016/j. otohns.2003.12.003/.
8. Gill J.M., Fleischut P., Haas S., Pellini B., Crawford A., Nash D.B. Use of antibiotics for adult upper respiratory infections in outpatient settings: a national ambulatory network study. Family medicine. 2006;38:349-354.
9. Nosulya E.V. Antibiotics in the treatment of bacterial rhinosinusitis: possibilities and limitations. Russian Rhinology. [Rossijskaya rinologiya.] 2014;22(3):36-40.] (In Russ.)
10. Möller W., Schuschnig U., Meyer G., Mentzel H., Keller M. Ventilation and drug delivery to the paranasal sinuses: studies in a nasal cast using pulsating airflow. Rhinology. 2008;46(3):213-220.
11. Boe J., Dennis J.H. European Respiratory Society Nebulizer Guidelines: Technical Aspects. Eur Respir Rev. 2000;72(10):1-237.
12. Pshennikov D.S. Prospects of inhalation therapy of acute rhinosinusitis. Science of young people [Nauka molodyh]. 2017;2:277-282.. https://doi.org/10.23888/ HMJ20172277-282.] (In Russ.)
13. Dennis JH. A review of issues relating to nebulizer standards. J Aerosol Med. 1998;11(Suppl 1):73-79.
14. Grassi C. & De Benedetto F. Recent Clinical Evidence of the Efficacy and Safety of Thiamphenicol Glycinate Acetylcysteinate and Thiamphenicol Glycinate. Journal of Chemotherapy. 2002;14(3):279-284. doi: 10.1179/joc.2002.14.3.279.
15. Kolosova N.G., Dronov I.A. Topical inhalation antibacterial therapy of respiratory infections in children. RMJ [RMZh]. 2017;5:319-32.] (In Russ.)
16. Chuchalin A.G., Soodaeva S.K., Avdeev S.N. Fluimucil: mechanisms of action and significance in the treatment of respiratory diseases. M.: Zambon Group S.P.A, 2004.] (In Russ.)
17. Macchi A., Ardito F., Marchese A., Schito G.C. & Fadda G. Efficacy of N-Acetyl-Cysteine in Combination with Thiamphenicol in Sequential (Intramuscular/Aerosol) Therapy of Upper Respiratory Tract Infections Even When Sustained by Bacterial Biofilms. Journal of Chemotherapy. 2006;18(5):507-513. doi: 10.1179/joc.2006.18.5.507.
18. Tullio V., Cuffini, A. Mandras N., Roana J., Banche G., Ungheri D., Carlone N. Influence of thiamphenicol on the primary functions of human polymorphonuclear leucocytes against Streptococcus pyogenes. International Journal of Antimicrobial Agents. 2004 October;24(4):381-385. https://doi.org/10.1016/j.ijantimicag.2004.03.027.
19. Mazzei T. Thiamphenicol: pharmacokinetic and safety considerations. GIMMOC. 2000;4:15-19.
20. Dinicola S., De Grazia S., Carlomagno G., Pintucci J.P. N-acetylcysteine as powerful molecule to destroy bacterial biofilms. A systematic review. Eur Rev Med Pharmacol Sci. 2014;18(19):2942-2948.
21. Aslam S., Darouiche R.O. Role of antibiofilmantimicrobial agents in controlling devicerelated infections. Int. J. Artif. Organs. 2011;34(9):752-758.
Review
For citations:
Morozova SV, Svistushkin VM, Karapetyan LS. Multidirectional inhalation therapy of acute rhinosinusitis. Meditsinskiy sovet = Medical Council. 2019;(8):28-32. (In Russ.) https://doi.org/10.21518/2079-701X-2019-8-28-32
Views:
864
Email this article 